Evidence map›Paper›PMID 34786251›Full record

ReviewCureus2021

Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer.

Moayad Alhumaid, Salma Sait, Emad Fallatah, Nasser AlSayegh, Ali Farsi, Mohammed Nassif, Nada J Farsi, Nouf Akeel, Ali Samkari, Alaa A Shabkah and 1 more

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Moayad AlhumaidDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Salma SaitDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Emad FallatahDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Nasser AlSayeghDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Ali FarsiDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Mohammed NassifDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Nada J FarsiDepartment of Dental Public Health, King Abdulaziz University Faculty of Dentistry, Jeddah, SAU.
Nouf AkeelDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Ali SamkariDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Alaa A ShabkahDepartment of Surgery, International Medical Center, Jeddah, SAU.
Nora TrabulsiDepartment of Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
King Abdulaziz University · SAKing Abdullah International Medical Research Center · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among patients with metastatic colorectal cancer, 25% have isolated peritoneal carcinomatosis. We performed a systematic review and meta-analysis to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing hyperthermic intraperitoneal chemotherapy with oxaliplatin. Eleven studies were included in the final assessment. Pooled three- and five-year OS rates were 58.60% and 42.19%, respectively. The estimated pooled three- and five-year DFS rates were 23.47% and 14.26%, respectively.

Indexed as

colorectal neoplasmcytoreductive surgery and hipeccytoreductive surgery (crs)oxaliplatinperitoneal carcinomasystematic review and meta-analysis

Identifiers

PMID34786251
PMCPMC8579872
OpenAlexW3205765195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.